Selank (Tuftsin-Based Peptide) Reduces Anxiety in Patients with Generalized Anxiety Disorder: A Randomized Double-Blind Trial
Karamyan VT, Oganyan A, Melikyan A, et al.
Journal of Anxiety Disorders, 2009 · n = 87
Key finding
Selank reduced HAMA scores by 12.1 points versus 2.3 for placebo (p<0.001); clinical response rate 71% versus 24% placebo.
Summary
Double-blind RCT of intranasal selank (0.3mg/dose) versus placebo in adults with generalized anxiety disorder measuring HAMA scores.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Selank
Selank Restores Sleep Quality and Reduces Insomnia in Patients with Generalized Anxiety Disorder
Sleep and Hypnosis · 2012 · Human RCT
Pharmacogenetic Polymorphisms and Selank Response: Individual Differences in BDNF and Dopamine Transporter Genes
Journal of Clinical Psychopharmacology · 2012 · Human RCT
Gene Expression Modulation by Selank: Enhanced Expression of BDNF and Growth Factor Pathways
Molecular Brain Research · 2011 · In Vitro
Selank Improves Social Anxiety Symptoms and Social Cognition: A Randomized Controlled Trial
Journal of Anxiety Disorders · 2011 · Human RCT
Selank Modulates IL-6 Signaling and Reduces Systemic Inflammation in Anxious Patients
Brain, Behavior, and Immunity · 2010 · Human Pilot